Volumetric tumor growth in advanced non-small cell lung cancer patients withEGFRmutations during EGFR-tyrosine kinase inhibitor therapy
出版年份 2013 全文链接
标题
Volumetric tumor growth in advanced non-small cell lung cancer patients withEGFRmutations during EGFR-tyrosine kinase inhibitor therapy
作者
关键词
-
出版物
CANCER
Volume 119, Issue 21, Pages 3761-3768
出版商
Wiley
发表日期
2013-08-07
DOI
10.1002/cncr.28290
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Measurement of Tumor Volumes Improves RECIST-Based Response Assessments in Advanced Lung Cancer
- (2014) P. David Mozley et al. Translational Oncology
- Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI
- (2013) Mizuki Nishino et al. Journal of Thoracic Oncology
- Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
- (2012) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Analyzing the Pivotal Trial That Compared Sunitinib and IFN- in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
- (2012) W. D. Stein et al. CLINICAL CANCER RESEARCH
- The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations
- (2012) S. Heon et al. CLINICAL CANCER RESEARCH
- Tumor Assessment Criteria in Phase I Trials: Beyond RECIST
- (2012) Antonin Levy et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
- (2012) Kenichi Nishie et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
- (2012) Mizuki Nishino et al. LUNG CANCER
- Imaging of Lung Cancer in the Era of Molecular Medicine
- (2011) Mizuki Nishino et al. ACADEMIC RADIOLOGY
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Tumour growth rates and RECIST criteria in early drug development
- (2011) Carlos Gomez-Roca et al. EUROPEAN JOURNAL OF CANCER
- Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer
- (2011) Margaret M. Kozak et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer
- (2010) Mizuki Nishino et al. ACADEMIC RADIOLOGY
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence
- (2010) P. D. Mozley et al. ANNALS OF ONCOLOGY
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
- (2010) S. Heon et al. CLINICAL CANCER RESEARCH
- Tumor Volume Is a Prognostic Factor in Non–Small-Cell Lung Cancer Treated With Chemoradiotherapy
- (2010) Brian M. Alexander et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer
- (2009) Binsheng Zhao et al. RADIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Volume Combined With Number of Positive Lymph Node Stations Is a More Important Prognostic Factor Than TNM Stage for Survival of Non–Small-Cell Lung Cancer Patients Treated With (Chemo)radiotherapy
- (2007) Cary Dehing-Oberije et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started